Mr. Jakob Brix Christensen has been appointed CFO of BioPorto from January 1, 2016. Jakob has more than 10 years’ experience from financial management positions within medtech/life-science companies in Denmark and US. Mr. Jakob Brix Christensen was previously member of the management team of Novozymes Biopharma (now Albumedix a/s) and before that Director of Investor Relations and US CFO at Origio. In addition to that Mr. Jakob Brix Christensen has been with GN Resound, Handelsbanken Capital Markets and Ernst&Young. Mr. Jakob Brix Christensen holds an MSc in Economics and Business administration from Aarhus Business School and a Graduate Diploma in Financial and Management Accounting (HD-R), supplemented by management training at Richmond University and Chicago Booth School of Business.
Financial management